- Home
- OGI vs AMRN Comparison
OGI vs AMRN Comparison
Compare OGI & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- AMRN
- Stock Information
- Founded
- OGI 2013
- AMRN 1989
- Country
- OGI Canada
- AMRN Ireland
- Employees
- OGI N/A
- AMRN N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- OGI Health Care
- AMRN Health Care
- Exchange
- OGI Nasdaq
- AMRN Nasdaq
- Market Cap
- OGI 165.0M
- AMRN 191.2M
- IPO Year
- OGI N/A
- AMRN 1993
- Fundamental
- Price
- OGI $1.59
- AMRN $0.47
- Analyst Decision
- OGI
- AMRN Buy
- Analyst Count
- OGI 0
- AMRN 1
- Target Price
- OGI N/A
- AMRN N/A
- AVG Volume (30 Days)
- OGI 726.1K
- AMRN 1.6M
- Earning Date
- OGI 02-11-2025
- AMRN 10-30-2024
- Dividend Yield
- OGI N/A
- AMRN N/A
- EPS Growth
- OGI N/A
- AMRN N/A
- EPS
- OGI N/A
- AMRN N/A
- Revenue
- OGI $110,297,722.00
- AMRN $241,021,000.00
- Revenue This Year
- OGI $8.76
- AMRN N/A
- Revenue Next Year
- OGI $14.04
- AMRN N/A
- P/E Ratio
- OGI N/A
- AMRN N/A
- Revenue Growth
- OGI 2.33
- AMRN N/A
- 52 Week Low
- OGI $1.21
- AMRN $0.45
- 52 Week High
- OGI $2.91
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- OGI 57.86
- AMRN 38.11
- Support Level
- OGI $1.45
- AMRN $0.45
- Resistance Level
- OGI $1.73
- AMRN $0.50
- Average True Range (ATR)
- OGI 0.10
- AMRN 0.03
- MACD
- OGI 0.02
- AMRN -0.00
- Stochastic Oscillator
- OGI 74.19
- AMRN 12.50
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.